RxDoctor Payments Data

Trung Dinh, MD

Family Medicine · Cypress, TXNPI 1083710271

Payments from drug & device makers

$754in general payments, 2019–2025

Across 37 payments — averaging $20.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$160
  • Amgen$126
  • GSK$93
  • Abbott$61
  • Lilly USA, LLC$54
  • Sanofi Pasteur Inc.$38
  • plus $222 from 10 others

What the payments were for

  • Food & beverage$73998%
  • Education$152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$754 in reported general payments places this provider in the 55th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$211,631
Medicare patients
170
Services billed
2,526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$97,165
Tresiba Flextouch U-100Insulin Degludec41$38,422
JanuviaSitagliptin Phosphate17$20,935
JardianceEmpagliflozin19$20,520
FarxigaDapagliflozin Propanediol19$20,399
ArexvyRsvpref3 Antigen/As01e/Pf45$14,028
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$4,124
Atorvastatin Calcium354$2,998
Losartan Potassium147$1,771
Tamsulosin Hcl109$1,687
Gabapentin71$1,673
PaxlovidNirmatrelvir/Ritonavir26$1,429
Azelastine Hcl36$1,322
SynthroidLevothyroxine Sodium12$1,309
Albuterol Sulfate HfaAlbuterol Sulfate51$1,178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$160$97,16580 claims
MerckJanuvia$26$20,93517 claims
Boehringer IngelheimJardiance$27$20,52019 claims
AstraZenecaFarxiga$37$20,39919 claims
GSKArexvy$93$14,02845 claims
AbbVieSynthroid$19$1,30912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Cypress

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →